Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.
Soheila RezaeiBehzad FatemiZahra Karimi MajdHossein MinaeiMohammad PeikanpourNassim AnjidaniAli TaheriFarzaneh DastanReza MosaedPublished in: Expert review of clinical immunology (2021)
Tocilizumab can improve clinical outcomes and reduce mortality rates in severe to critical COVID-19 patients. Large-scale randomized controlled trials are still required to improve the statistical power of meta-analysis.
Keyphrases
- sars cov
- rheumatoid arthritis
- systematic review
- meta analyses
- randomized controlled trial
- juvenile idiopathic arthritis
- coronavirus disease
- rheumatoid arthritis patients
- early onset
- cardiovascular events
- risk factors
- cardiovascular disease
- drug induced
- clinical trial
- coronary artery disease
- study protocol
- systemic lupus erythematosus